Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT03041688 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 58 | National Cancer Institute (NCI)NIH |
| 1 |
| Jun 11, 2026 |
| clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03983824 | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04190550 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | not yet recruiting | Phase 2 | 110 | Hematology department of the 920th hospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07588360 | Haplo-Cord HSCT for AML/MDS | recruiting | N/A | 82 | Fujian Medical University Union HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07627568 | Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.(AML_MenALLO) | recruiting | — | 20 | University of FreiburgOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07635485 | VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML | not yet recruiting | N/A | 50 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03422731 | Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | active not recruiting | Early Phase 1 | 82 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03586609 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06535113 | Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia(Inflamm-AML) | recruiting | — | 80 | Ciceri FabioOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06131801 | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | recruiting | — | 30 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03921047 | Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | recruiting | — | 250 | University of Southern CaliforniaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623616 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | recruiting | Phase 2 | 6 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06372717 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | recruiting | Phase 1 | 100 | Apollo Therapeutics LtdINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT07617285 | Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML | recruiting | Phase 1 | 27 | Peking University People's HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617363 | ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS | not yet recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02091245 | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | active not recruiting | Phase 1 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | recruiting | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06370000 | Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality(REMAIN1) | recruiting | Phase 4 | 12 | Virginia Commonwealth UniversityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06445907 | Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors(FXS0683-001) | not yet recruiting | Phase 1 | 228 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | May 28, 2026 | clinicaltrials |
| NCT04953897 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment | recruiting | Phase 1 | 18 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT04953910 | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment | recruiting | Phase 1 | 27 | Taiho Oncology, Inc.INDUSTRY | 8 | May 28, 2026 | clinicaltrials |
| NCT07607327 | Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)(FORWARD) | not yet recruiting | — | 400 | CareDxINDUSTRY | 1 | May 26, 2026 | clinicaltrials |
| NCT07607418 | Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02632708 | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | active not recruiting | Phase 1 | 153 | Institut de Recherches Internationales ServierOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT03589729 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers | recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01409161 | Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia | recruiting | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia | recruiting | Phase 2 | 508 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03613532 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | active not recruiting | Phase 1 | 102 | Jacqueline Garcia, MDOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03747757 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04774393 | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 84 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07598110 | FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML(FT-RIC-HAPLO) | not yet recruiting | Phase 2 | 77 | Institut Paoli-CalmettesOTHER | 0 | May 20, 2026 | clinicaltrials |
| NCT04318678 | CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | recruiting | Phase 1 | 108 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | recruiting | Phase 1 / Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT03326921 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | recruiting | Phase 1 | 24 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04380441 | Quality of Life Model for Older Patients With AML | active not recruiting | — | 206 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05133882 | A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML | recruiting | Phase 1 / Phase 2 | 133 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 11, 2026source: clinicaltrials